Completed PHASE2 INTERVENTIONAL 1-arm NCT00856791

Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients

Phase II Single-arm Study of ON 01910.Na by 2-hr Infusion in Patients With Recurring Platinum-resistant Ovarian Cancer

Sponsor: Traws Pharma, Inc.

Interventions ON 01910.Na

Updated 9 times since 2017 Last updated: Jun 22, 2017 Started: Mar 31, 2009 Primary completion: Jul 31, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Ovarian Cancer and is currently completed. Traws Pharma, Inc. leads this study, which shows 9 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2024 — Jul 2024 [monthly]

Completed PHASE2
Jan 2023 — Jun 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Traws Pharma, Inc.

Data source: Traws Pharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Indianapolis, United States